Aviceda Therapeutics is winding down after a Phase 2 failure tied to its eye-disease drug development strategy, according to a source familiar with the company’s decision-making. The company had been planning to push an eye drug into Phase 3 even after the mid-stage setback, but the outcome ultimately led to liquidation-style exit planning rather than continued burn toward a later-phase readout. The move highlights the financial fragility typical in ophthalmology-focused biotechs when Phase 2 endpoints do not translate into a clear path to confirmatory efficacy. For investors and partners, it also reinforces how quickly clinical risk can cascade into operational decisions. Sector-wide, Aviceda’s shutdown is another example of the pipeline “attrition” pressures facing smaller companies, especially when timelines depend on moving swiftly to Phase 3 before additional funding becomes harder to secure.